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Abstract
Introduction and hypothesis Urinary dipsticks and culture
analyses of a mid-stream urine specimen (MSU) at 105 cfu
ml−1 of a known urinary pathogen are considered the gold
standard investigations for diagnosing urinary tract infection
(UTI). However, the reliability of these tests has been much
criticised and theymaymislead. It is nowwidely accepted that
pyuria (≥1 WBC μl−1) detected by microscopy of a fresh
unspun, unstained specimen of urine is the best biological
indicator of UTI available. We aimed to scrutinise the greater
potential of symptoms analysis in detecting pyuria and UTI.
Methods Lower urinary tract symptom (LUTS) descriptions
were collected from patients with chronic lower urinary tract
symptoms referred to a tertiary referral unit. The symptoms
informed a 39-question inventory, grouped into storage,
voiding, stress incontinence and pain symptoms. All questions
sought a binary yes or no response. A bespoke software pack-
age was developed to collect the data. The study was powered
to a sample of at least 1,990 patients, with sufficient power to
analyse 39 symptoms in a linear model with an effect size of
Cohen’s f2 = 0.02, type 1 error probability = 0.05; and power
(1-β); 95% where β is the probability of type 2 error). The
inventory was administered to 2,050 female patients between
August 2004 and November 2011. The data were collated and
the following properties assessed: internal consistency, test–
retest reliability, inter-observer reliability, internal responsive-
ness, external responsiveness, construct validity analysis and a
comparison with the International Consultation on
Incontinence Modular Questionnaire for female lower urinary
tract symptoms (ICIQ-FLUTS). The dependent variable used
as a surrogate marker of UTI was microscopic pyuria. An
MSU sample was sent for routine culture.
Results The symptoms proved reliable predictors of micro-
scopic pyuria. In particular, voiding symptoms correlated well
with microscopic pyuria (χ2 = 88, df = 1, p < 0.001). The
symptom inventory has significant psychometric characteris-
tics as below: test–retest reliability: Cronbach’s alpha was
0.981; inter-observer reliability, Cronbach’s alpha was 0.995,
internal responsiveness F = 221, p < 0.001, external respon-
siveness F = 359, df = 5, p < 0.001. The correlation coeffi-
cients for the domains of the ICIQ-FLUTS were around
R = 0.5, p < 0.001.
Conclusion This symptoms score performed well on the stan-
dard, psychometric validation. The score changed in response
to treatment and in a direction appropriate to the changes in
microscopic pyuria. It correlated with measures of quality of
life. It would seem to make a good candidate for monitoring
treatment progress in ordinary clinical practice.
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Introduction
Urinalysis by dipstick and/or midstream urine culture (MSU)
is the first investigation of the patient presenting with lower
urinary tract symptoms (LUTS). Negative results are usually
assumed to exclude infection and diagnoses such as overac-
tive bladder (OAB) depend on negative tests. TheMSU is still
considered the gold standard diagnostic test for UTI. It relies
on isolating 105 cfu ml−1 of a known urinary pathogen, using
aerobic culture with a Enterobacteriaceae-selective media.
This was first described by Kass [1] after studying patients
with chills, fever, flank pain and dysuria. Kass never claimed
to define a threshold for use with Bcystitis^, i.e. frequency/
dysuria. However, 105 cfu ml−1 has been widely adopted.
The dipstick has been validated against a standard of 105 cfu
ml−1 of a known urinary pathogen.
In fact, these urinalysis methods are not sensitive and are
incapable of excluding UTI. Effort is being made to find im-
proved urinalysis techniques to detect UTI [2], but currently
the best performing method is microscopy of a fresh unspun,
unstained, clean-catch specimen of urine in a counting cham-
ber to enumerate the white cells [3].
Our past reliance on dipstick analysis and culture to diag-
nose UTI has now been rejected in the literature [4], we should
therefore re-examine our understanding of the symptoms and
signs involved in LUTS [5].
The analysis of symptoms presents different challenges to
the measurement of change over time, when assessing treat-
ment outcomes. Well-known validated scores of LUTS such
as the International Consultation on Incontinence
Questionnaire (ICIQ), [6] the Incontinence Quality of Life
Questionnaire (ICI-QOL) [7] and Female Lower Urinary
Tract Symptoms (F-LUTS) [8] are used to assess the impact
of incontinence. They have performed well in measuring the
effects of treatments in clinical trials. Their utility in single,
cross-sectional analyses is less assured because they use ad-
jectival scaling such as Bbothersomeness^. People differ great-
ly in their semantic interpretation of adjectives. In longitudinal
studies, the potential error from this variance can be avoided
by the normalisation of within subject changes. This option is
available to neither cross-sectional studies, nor to data collect-
ed at the time of diagnostic assessment. Additionally, scores
such as the ICIQ were validated in patients after UTI had been
excluded on the evidence of urine culture. Our interest lies in
the symptoms associated with reliable indicators of UTI.
We aimed to design a symptom analysis method, free of
adjectival scaling, covering the spectrum of LUTS.Wewished
to avoid selecting symptoms based on our assumptions. The
symptom inventory was constructed from sets collected from
patients who, unconstrained, described their experience of
disease. We chose to use BYes/No^ responses to enquiry to
avoid adjectival qualification. We have reported this approach
in developing descriptive measures in several different cir-
cumstances. We have found that it is possible to achieve valid
scaling by counting the different circumstances that aggravate
a patient’s symptoms.
The study aim was to build a symptoms inventory from the
patient’s descriptions of their experiences. Once assured that
this could be applied by using dichotomised responses, we
planned to validate the psychometric properties of the ques-
tionnaire. We then planned to examine the relationship to the
pathological condition by regression analysis on microscopic
pyuria, which is currently our best marker of UTI [3, 9]. We
also arranged to test the responsive properties of the question-
naire during treatment.
Materials and methods
Ethics committee approval was obtained from the East
London and the City Research Ethics Committee. All patient
data were anonymized after collection.
The evolution of the symptom set
The first task was to identify symptoms that described, as
thoroughly as possible, the experience of lower urinary tract
infections (LUTS) from the patients’ perspective in patients
referred with chronic LUTS to a tertiary referral centre. A
computer programme was created that enabled a clinician to
record symptoms while the patients narrated them. The soft-
ware functioned to accumulate lists that were easy to add to. A
core set of ubiquitous symptoms rapidly evolved, with rarer
and idiosyncratic experiences being added as more patients
participated. At the end of their narrative, patients were asked
if they were confident that they had described everything. This
method was deployed in our ordinary clinical service between
1991 and 1999.
In 1999, the data were analysed and we extracted all symp-
toms that occurred at least as frequently as dysuria (≥2% of
respondents), because the latter is an archetypal symptom of
cystitis. These questions were then grouped into the four main
categories: storage and voiding symptoms, stress urinary in-
continence (SUI) and pain. These questions were organised
into an inventory that was used to elicit symptoms from pa-
tients by direct questioning, recording a Byes^ or Bno^ re-
sponse. The patients were always asked to supplement the
information with additional material applicable to their expe-
rience. In 2004, the data were analysed again and a final in-
ventory was constructed from those symptoms described by
≥2% of respondents. These 39 questions are listed in Table 1.
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These two preparatory phases sampled males and females
so as to avoid a gender bias in the structure of the final symp-
tom inventory.
Validation of the symptom set
The 39-question set was written into a new database and from
2004 these questions were included in the assessment of all
adult (≥18 years) patients with untreated LUTS, presenting to
a secondary care facility attached to urology and
urogynaecology departments. The observers presented the
question set by using a script (see Appendix Table 4). The
reported 24-h urinary frequency and incontinence were re-
corded. A group of normal control subjects also contributed
data.
At the time of assessment, a clean-catch midstream urine
sample was collected as described below. From this an imme-
diately fresh, unspun, unstained specimen was examined in a
haemocytometer as described below. An aliquot was
despatched for routine culture, as described below.
The first part of the data analysis involved psychometric
validation according to the methods described below.
Reliability
1. Internal consistency, which measured the within-group
agreement, when the questions were collected into the
following categories: storage symptoms, voiding symp-
toms, SUI symptoms and pain symptoms. This was
assessed by calculation of Cronbach’s alpha coefficient.
2. Test–retest reliability, which measured the consistency of
the symptom inventory when repeated in the same patient.
This was done by allowing each patient to complete the
symptom set twice within 2 days, so that the symptoms
were unlikely to have changed.We used Cronbach’s alpha
coefficient for the paired data.
3. Inter-observer reliability, which measured the consistency
of the symptom inventory when performed by different
observers of the same patient. This was carried out by two
observers questioning the same patient independently
during the same clinic attendance. We used Cronbach’s
alpha coefficient for the paired data.
Thus, reliability was assessed according to the ICIQ guide-
lines [6].
Responsiveness
1. Internal responsiveness, the ability of the symptom set to
detect change, was measured by comparing the symptoms
over four successive follow-up visits during treatment.
The patients were treated for LUTS symptoms, using
bladder retraining, antimuscarinic drugs for OAB
symptoms and antibiotics if microscopic pyuria was iden-
tified. The response was assessed using mixed model lin-
ear regression.
2. External responsiveness was analysed first by comparing
of the symptom score with the patient’s grading of the
treatment response on the scale: Bworse^, Bno change^,
Bmild improvement^, Bmoderate improvement^, Bmarked
improvement^, and second by comparing the inventory
with 24-h frequency and 24-h incontinence. The response
was assessed using mixed model linear regression.
3. Construct validity analysis formed the crux of this study.
We explored the inferences that could be drawn from
symptom occurrence in relation to the probability of sig-
nificant microscopic pyuria, the latter being our best indi-
cator of UTI. To analyse this, we used mixed model linear
regression.
Comparison with FLUTS
We collected data from 135 patients who completed an
International Consultation on Incontinence Modular
Questionnaire for female lower urinary tract symptoms
(ICIQ-FLUTS) [8] and compared the FLUTS subgroup scores
with the number of symptoms detected by our inventory
grouped according to the four categories: urgency, stress,
voiding and pain. We used Spearman’s correlation coefficient.
Urinalysis methods
The MSU samples were obtained by the midstream clean-
catch method described elsewhere [10]. The microscopic leu-
cocyte count was achieved as follows: a fresh aliquot of urine
was split into two and examined by microscopy. 1 μl of urine
was loaded into a clean Neubauer haemocytometer counting
chamber [11] and the preparation examined by light micros-
copy (magnification, ×200). The white cells were counted per
1 μl. These data were collected by specially trained doctors
and nurses. A routine MSU culture was performed as follows:
an aliquot of all urine specimens collected was sent to the
Whittington Hospital NHS Trust microbiology laboratory, as
is routinely done, for culture using standard methods [10] The
result was taken as positive if at least 105 colony-forming units
(cfu) ml−1 of a known pathogen were present, after 18–24 h of
culture.
Statistics
We used a mixed model linear regression analysis to scrutinise
the log10 WBC as the response variable. This method is de-
signed for repeatedmeasures and copes with missing data cells.
We had to address the occurrence of an excess of zero WBC
counts and achieved this by using the glmmADMB procedure
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in R to construct a zero-inflated negative binomial regression
model to accommodate over-dispersion of the data; the regres-
sionmodel was specified for themean of the negative binomial.
The zero WBC counts were expressed as very small numbers
for the log10 transformation. The symptoms were treated as
individual independent variables (39) questions.
To accommodate an interpretation, commensurate with
common clinical practice, the patients were additionally
grouped according to their pyuria counts: zero, pyuria 1–9
or pyuria ≥10, and then the symptoms were plotted against
these groups (see Fig. 4) We did this because of the wide-
spread use of pyuria ≥10 WBC μl−1 as the threshold for
Bsignificant^ pyuria [12], although results that incriminate py-
uria between 1 and 9 have been published [2].
To compare the voiding and pain symptoms among the
three categories of pyuria, we used ordinal regression with
the category as the dependent variable and the number of
voiding symptoms and pain symptoms as covariates.
We used a two-tailed non-parametric test with an ef-
fect size (d) = 0.5, which means that an effect in either
direction would be interpreted. The criterion for signif-
icance (probability of alpha error) was set at 0.050 and
a power of 80% (1-beta error of probability = 0.8).
With the proposed sample size of 170 for the two
groups (43 controls and 127 patients), the study had a
power of 80% to yield a statistically significant result
with an effect size d = 0.5.
Cohen’s d effect size = 0.5 (Fig. 1) was selected, as this is
the smallest effect that it would be important to detect, in the
sense that any smaller effect would not be of clinical or sub-
stantive significance. It was also assumed that this effect size
is reasonable, in the sense that an effect of this magnitude
could be anticipated in this field of research. Cohen’s d is
defined as the mean difference expressed in standard
deviations. d = difference between means ÷ pooled standard
deviations of the two groups.
The sample of at least 1,990 patients had sufficient power
to analyse 39 predictor symptoms.Missing data were recorded
as null fields.
Results
The first data set was collected between January 1991 and
July 1999 and analysed when the software was re-written to
accommodate the millennium bug threat. It contained data
from 2,446 patients; 2,019 (82%) female and 427 (18%) male
with a mean age of 53 (SD = 19). During 7,467 consultations,
they provided 65,535 data entries. The first question set, made
up of each symptom being described by ≥2% of respondents,
consisted of those depicted in Table 1 apart from questions 29
to 33.
The second data set, collected between August 1999 and
July 2004, was analysed once we had validated our method
for counting pyuria. There were data on 2,109 patients; 1,836
(87%) female and 273 (13%) male with a mean age of 52
(SD = 30). There were 7,046 consultations that provided
54,159 data entries. This analysis resulted in modification of
the description of bladder pain, which was expanded into a
four-question set: bladder pain or discomfort on filling; filling
bladder pain relieved by voiding; filling bladder pain partially
relieved by voiding; (filling bladder pain unrelieved by
voiding (questions 29 to 33 in Table 1). We did this because
these symptom qualifications, referring to voiding, were de-
scribed by ≥2% of respondents (Table 1).
During the study phase, the LUTS symptom inventory was
administered to 2,050 female patients presenting between
August 2004 and November 2011. Their mean age 52
Table 1 Symptom inventory in the order in which the questions are asked
Storage symptoms Stress symptoms Voiding symptoms Pain symptoms
1. Urgency 12. Cough sneeze incontinence 20. Hesitancy 27. Suprapubic pain
2. Urge incontinence 13. Exercise incontinence 21. Reduced stream 28. Filling bladder pain
3. Latchkey urgency 14. Laughing incontinence 22. Intermittent stream 29. Voiding bladder pain
4. Latchkey urgency incontinence 15. Passive incontinence 23. Straining to void 30. Post-void bladder pain
5. Waking urgency 16. Bending incontinence 24. Terminal 31. Pain relieved by voiding
6. Waking urge incontinence 17. Incontinence 25. Post-void dribbling 32. Partially voiding relief
7. Running water urgency 18. Lifting incontinence 26. Double voiding 33. No voiding relief
8. Running water urge incontinence 19. Pre-cough preparation 34. Loin pain
9. Cold urgency 35. Iliac fossa pain
10. Anxiety urgency 36. Pain radiation to genitals
11. Premenstrual aggravation 37. Pain radiation to legs
38. Dysuria
39. Urethral pain
Questions 29 to 32 were introduced in this format in 2004
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(SD = 17) and the average number of symptoms was 10
(SD = 5.9; median = 9), with a mean duration of symptoms
of 6 years (SD = 6). The considerable overlap between the
symptom groups is illustrated in the four-way Venn diagram
of Fig. 1.
A total of 1,305 patients (64%) had no pyuria at presenta-
tion, 356 patients (17%) had pyuria between 1 and 9 WBC
μl−1 and 389 (19%) had pyuria of ≥10 WBC μl−1. Two hun-
dred and forty-five patients (12%) demonstrated positive
MSU cultures.
Reliability
Internal consistency
Cronbach’s alpha for urgency was 0.88 with 11 items, for pain it
was 0.861 with 13 items, for stress incontinence 0.884 with 8
items and for voiding 0.882 with 7 items. When the symptoms
were counted within each group, Cronbach’s alpha was 0.35 for
the counts of urgency symptoms, stress incontinence symptoms,
voiding symptoms and pain symptoms, confirming that the
symptoms between groups measured different things.
The theoretical value of alpha varies from zero to 1. Higher
values of alpha are more desirable. A reliability of 0.70 or
higher is often required as a consensus before an instrument
is used. 0.80–0.9 is good and >0.9 is excellent.
Test–retest reliability
Ten patients participated in the test–retest analysis.
Cronbach’s alpha was 0.981 with an inter-item correlation
coefficient of 0.974.
Inter-observer reliability
Ten patients participated in the inter-observer reliability anal-
ysis. Cronbach’s alpha was 0.995 with an inter-item correla-
tion coefficient of 0.991.
6% 
8% 
5% 
1% 
0.4%
6% 
8% 
3% 
4% 
8% 
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Fig. 1 Four-way Venn diagram
of symptom overlap
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Responsiveness
Internal responsiveness
A total of 2,050 patients provided data on follow-up over 4 visits
(24 weeks); the patients were treated with a combination of
antimuscarinics and antibiotics. Analysis showed a significant
reduction in the total number of symptoms F = 221, p < 0.001.
The tables from the mixed model analysis are shown in the
Appendix (Fig. 2)
External responsiveness
We examined external responsiveness by comparing the num-
ber of symptoms as the dependent variable using the follow-
ing independent variables: the patients’ assessment of overall
response; 24-h frequency; 24-h incontinence.
The results were as follows. Overall response: F = 359,
df = 5, p < 0.001; 24-h frequency: F = 255, p < 0.001; 24-h
incontinence: F = 320, p < 0.001. Figure 3 plots the number of
symptoms against the patients’ overall assessment of re-
sponse, the 24-h urinary frequency, and urinary incontinence.
Construct validity
The zero-inflated negative binomial regression model param-
eter estimates and statistics, with pyuria (WBC μl−1) as the
dependent variable; repeated measures identified by visit
number; and with the independent covariates being age, 25-
frequency and 24-h incontinence and the 39 symptoms
(No = 0 Yes = 1) are shown in Table 2. Age, 24-h frequency,
24-h incontinence, urge incontinence, latchkey incontinence,
bladder pain post-void, dysuria and reduced stream explained
a significant proportion of the variance in log10 pyuria; exer-
cise incontinence, passive incontinence and pre-cough
guarding were negative explanatory variables.
The clinical implications
Comparison with FLUTS
The correlation between the FLUTS subgroups and the
grouped symptoms from our inventory are shown in Table 3.
The coefficients range from 0.36 to 0.57 and it is interesting
that these were greatest for the voiding symptoms.
Symptom implications
The core aim was to examine the relationship between the
symptoms and microscopic pyuria as the best marker of
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UTI. The MSU cultures, only 12% positive, were not suitable
for such analysis. An important finding was the prominence of
voiding symptoms as indicators of pyuria. In particular, these
seemed to be most discerning in the milder expressions of the
disease. Figure 4 plots the voiding symptoms count
(covariate) against the pyuria groups (dependent ordinal vari-
able; zero, 1 to 9, ≥ 10) in patients not describing pain
(χ2 = 88, df = 1, p < 0.001). The voiding symptoms count
discriminated among all three categories. The pain symptom
count only discriminated between zero pyuria and any pyuria
(χ2 = 148, df = 1, p < 0.001; Fig. 5).
Discussion
Amost important finding from this study has been the discov-
ery that in women, voiding symptoms play an important part
in the complex associated with pyuria, pain features but is
only evident for the higher levels of pyuria; it would seem that
voiding symptoms are more discriminating.
There are many symptom scores reported in the literature
that measure the experience of lower urinary tract disease, de-
signed and validated by others.Wewould not have invested the
effort required to develop this inventory without good reason.
Table 2 Zero-inflated negative binomial regression model parameter estimates and statistics
Coefficients Estimate of BB^ Standard error z value p value Significance (p value)
Intercept BC^ −0.07561 0.22852 −0.33 0.74075
Age 0.0292 0.0034 8.59 < 2e-16 <0.001
24-h frequency −0.04465 0.01216 −3.67 0.00024 <0.001
24-h incontinence 0.10157 0.04891 2.08 0.03784 <0.05
Urgency 0.00945 0.15417 0.06 0.95113
Urgency incontinence −0.50046 0.16189 −3.09 0.00199 <0.001
Latchkey urgency 0.07889 0.1533 0.51 0.60682
Latchkey incontinence 0.51879 0.1881 2.76 0.00581 <0.001
Waking urgency 0.07302 0.14919 0.49 0.62454
Waking urgency incontinence 0.34714 0.17846 1.95 0.05175
Running water urgency −0.19246 0.15407 −1.25 0.2116
Running water urgency incontinence −0.04143 0.20421 −0.2 0.83922
Cold urgency 0.14011 0.1301 1.08 0.2815
Anxiety urgency 0.06066 0.13452 0.45 0.65202
Perimenstrual symptom aggravation −0.02327 0.21281 −0.11 0.91291
Suprapubic pain 0.13497 0.14545 0.93 0.35344
Filling bladder pain 0.30853 0.31115 0.99 0.3214
Voiding bladder pain 0.25012 0.17 1.47 0.14121
Post-void bladder pain 0.45377 0.1505 3.02 0.00257 <0.001
Pain relieved by voiding −0.42165 0.32854 −1.28 0.19935
Pain partially relieved by voiding −0.5755 0.32128 −1.79 0.07325
Pain unrelieved by voiding −0.27706 0.37857 −0.73 0.46425
Loin pain 0.25804 0.14409 1.79 0.07332
Iliac fossa pain 0.1135 0.14823 0.77 0.44384
Pain radiation to genitals −0.18812 0.15214 −1.24 0.21627
Pain radiation to legs −0.15892 0.17227 −0.92 0.35626
Dysuria 0.78097 0.15377 5.08 3.80E-07 <0.001
Urethral pain −0.00573 0.161 −0.04 0.9716
Stress incontinence 0.18834 0.15313 1.23 0.21872
Exercise incontinence −0.58106 0.20903 −2.78 0.00544 <0.001
Laughing incontinence 0.08031 0.21176 0.38 0.70449
Passive incontinence −0.43011 0.2182 −1.97 0.0487 <0.05
Bending incontinence −0.19502 0.24875 −0.78 0.43304
Standing incontinence 0.29879 0.24378 1.23 0.22033
Lifting incontinence −0.04617 0.22139 −0.21 0.83479
Preparing before coughing −0.86663 0.22553 −3.84 0.00012 <0.001
Hesitancy 0.20904 0.14249 1.47 0.14236
Reduced stream 0.51777 0.14893 3.48 0.00051 <0.001
Intermittent stream 0.24887 0.14587 1.71 0.08799
Terminal dribbling 0.20226 0.14053 1.44 0.15008
Double voiding 0.22458 0.14037 1.6 0.10961
Postmicturition dribbling 0.04447 0.15421 0.29 0.77305
Straining to void 0.04685 0.15315 0.31 0.75968
The bold entries are highly significant
Negative binomial was preferred to Poisson likelihood to accommodate overdispersion of the data
The regression model was specified for the mean of the negative binomial and an inflation parameter was estimated to account for the out-of-pattern
number of zeros
Regression (WBC ul−1 = Bixi + Bi+1 xi+1 +……. Bjxj + C + error)
Int Urogynecol J
There is a growing realisation that the methods used to screen
for urine infection in clinical practice are far from accurate and
that their sensitivities do not justify the given status as arbitra-
tors of the presence or absence of infection. We have recently
reported that in patients with chronic LUTS, the dipstick test is
at best 59% sensitive [3] and others have shown a diverse
urinary microbiome in patients with incontinence and urgency
when routine urine cultures are negative [9, 13]. In truth, we do
not have reliable methods for achieving such decisive diagno-
ses. We must therefore rely on the symptoms and signs, which
may be no bad thing. We must take a history, examine the
patient and not delegate the diagnostic decision to a single test.
The questionnaire that is described in this paper was de-
signed to measure the symptomatic manifestations of pyuria.
We could not validate against proven UTI because there is no
contemporary microbiological method capable of furnishing
the necessary data with sufficient accuracy. Microscopic py-
uria, measured by immediate microscopy of a fresh, unstained
and unspun specimen of urine in a haemocytometer is the best
marker of urinary infection that we have, despite its surrogacy
[2].
The 39 questions that make up the questionnaire had their
origin in the free texts collected when patients were asked to
describe their condition in their own words. Many of the early
years of this project were devoted to obtaining these data and
fashioning them into an inventory requiring dichotomized re-
sponses. Fidelity to the original source data was maintained
throughout so that the questionnaire was not altered to accom-
modate data from investigations or diagnostic categorization.
The correlates show that the patients’ own descriptions of their
states concur with the pathophysiology.
The symptoms score proved a good predictor of micro-
scopic pyuria and monitor of disease progression. The depen-
dent variable, pyuria, is the best surrogate marker of UTI
available. The score correlated with measures of quality of
life. Voiding symptomswere proved indicators of mild disease
with pain indicating more severe inflammatory responses.
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Table 3 Correlation between female lower urinary tract symptoms
(FLUTS) subgroups and grouped symptoms. Correlation matrix from
comparison with International Consultation on Incontinence Modular
Questionnaire (ICIQ)
Urgency
symptom
count
Stress
incontinence
symptom
count
Voiding
symptom
count
Pain
symptom
count
ICIQ-LUTS-QOL;
symptom score
(Pearson
correlation R)
0.449 0.434 0.449 0.346
ICIQ-LUTS-QOL;
bother score
(Pearson
correlation R)
0.464 0.408 0.444 0.352
ICIQ-FLUTS;
symptom score
(Pearson
correlation R)
0.487 0.419 0.543 0.365
ICIQ-FLUTS;
bother score
(Pearson
correlation R)
0.528 0.481 0.586 0.392
All of these coefficients were statistically significant at p < 0.001
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